<DOC>
	<DOCNO>NCT00881309</DOCNO>
	<brief_summary>The purpose study : - To access efficacy TW compare Aza maintenance therapy lupus nephritis - To investigate safety tolerability TW versus Aza maintenance therapy lupus nephritis</brief_summary>
	<brief_title>To Compare Efficacy Safety Tripterygium ( TW ) Versus AZA Maintenance Therapy Lupus Nephritis</brief_title>
	<detailed_description>Tripterygium ( TW ) Chinese traditional patent drug treat chronic glomerulonephritis . It use treat lupus nephritis many year less side effect . We compare efficacy safety TW v Aza maintenance therapy lupus nephritis .</detailed_description>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<criteria>1 . Patients sign write informed consent form ; 2 . SLE patient , age 1860 year , female male ; 3 . Patients diagnose lupus nephritis accord ISN/RPS 2003 classification criterion , class Ⅲ , Ⅳ , Ⅳ+Ⅴ , Ⅲ+Ⅴ Ⅴ LN renal biopsy ; 4 . All patient receive induction therapy 612 month , include MMF , CTX , FK506 multitarget therapy ; 5 . When recruit study , patient receive partial remission complete remission 3 month ; Complete remission : proteinuria &lt; 0.4 g/24h , negative urine sediment , serum albumin &gt; 35 g/L , elevate scr &lt; 0.3 mg/dl , extrarenal complication ; Partial remission : proteinuria &lt; 1.0 g/24h , urine RBC &lt; 500000/ml without cast , serum albumin &gt; 35 g/L , elevate scr &lt; 0.3 mg/dl , extrarenal complication . 1 . Patients n't sign write informed consent form could obey protocol ; 2 . Patients n't receive CR PR criterion ; 3 . Patients impaired liver function , ALT/GPT AST/GOT twice normal upper limit ; 4 . WBC &lt; 3000/mm3 peripheral blood ; 5 . Patients abnormal central nervous system .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>